Real-world experience with interferon-free, direct acting antiviral therapies in Asian Americans with chronic hepatitis C and advanced liver disease

Medicine (United States)

Volumn 96, Issue 6, 2017, Pages

  Chang, Christine Y ^a,b   Nguyen, Pauline ^a   Le, An ^a   Zhao, Changqing ^a,c   Ahmed, Aijaz ^a   Daugherty, Tami ^a   Garcia, Gabriel ^a   Lutchman, Glen ^a   Kumari, Radhika ^a   Nguyen, Mindie H ^a  

^a STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c SHANGHAI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

Author keywords

Asian Americans; Direct acting antivirals; Hepatitis C; Real world experience; Sofosbuvir

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; DACLATASVIR; INTERFERON; LEDIPASVIR; PEGINTERFERON; PROTON PUMP INHIBITOR; RIBAVIRIN; SIMEPREVIR; SOFOSBUVIR; TELAPREVIR; VIRUS RNA; ANTIVIRUS AGENT;

ADULT; ADVANCED CANCER; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANTIVIRAL THERAPY; ARTICLE; ASIAN AMERICAN; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BODY MASS; CHRONIC HEPATITIS C; DECOMPENSATED LIVER CIRRHOSIS; DECREASED APPETITE; DRUG DOSE REDUCTION; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; FATIGUE; FEMALE; HEADACHE; HEPATITIS C VIRUS GENOTYPE 1; HEPATITIS C VIRUS GENOTYPE 2; HEPATITIS C VIRUS GENOTYPE 3; HEPATITIS C VIRUS GENOTYPE 6; HUMAN; INSOMNIA; LIVER CELL CARCINOMA; LIVER GRAFT; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MIDDLE AGED; MYALGIA; NAUSEA; OBSERVATIONAL STUDY; PERSONAL EXPERIENCE; PHOTOSENSITIVITY; PRIORITY JOURNAL; PRURITUS; RASH; RETROSPECTIVE STUDY; SIDE EFFECT; SUSTAINED VIROLOGIC RESPONSE; TREATMENT RESPONSE; DOSE RESPONSE; DRUG EFFECTS; ETHNOLOGY; GENETICS; HEPACIVIRUS; HEPATITIS C, CHRONIC;

AGED; ANTIVIRAL AGENTS; ASIAN AMERICANS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SOFOSBUVIR; SUSTAINED VIROLOGIC RESPONSE;

EID: 85013870434     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000006128     Document Type: Article

References (47)

1. Mohd Hanafiah K, Groeger J, Flaxman AD, et al. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology 2013;57:1333-42.
2. World Health Organization. Hepatitis C. World Health Organization Fact Sheet (Revised July 2016). Available at: http://www.who.int/mediacentre/factsheets/fs164/en/ (accessed July 2016).
3. Nguyen LH, Nguyen MH. Systematic review: Asian patients with chronic hepatitis C infection. Aliment Pharmacol Ther 2013;37:921-36.
4. Westbrook RH, Dusheiko G. Natural history of hepatitis C. J Hepatol 2014;61:S58-68.
5. Stanaway JD, Shepard DS, Undurraga EA, et al. The global burden of dengue: an analysis from the Global Burden of Disease Study 2013. Lancet Infect Dis 2016;16:712-23.
6. Martinot-Peignoux M, Stern C, Maylin S, et al. Twelve weeks posttreatment follow-up is as relevant as 24 weeks to determine the sustained virologic response in patients with hepatitis C virus receiving pegylated interferon and ribavirin. Hepatology 2010;51:1122-6.
7. Shiratori Y, Imazeki F, Moriyama M, et al. Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy. Ann Intern Med 2000;132:517-24.
8. Chuang W-L, Yu M-L. Host factors determining the efficacy of hepatitis C treatment. J Gastroenterol 2013;48:22-30.
9. Matsuura K, Watanabe T, Tanaka Y. Role of IL28B for chronic hepatitis C treatment toward personalized medicine. J Gastroenterol Hepatol 2014;29:241-9.
10. Hepburn MJ, Hepburn LM, Cantu NS, et al. Differences in treatment outcome for hepatitis C among ethnic groups. Am J Med 2004;117:163-8.
11. Missiha S, Heathcote J, Arenovich T, et al. Impact of asian race on response to combination therapy with peginterferon alfa-2a and ribavirin in chronic hepatitis C. Am J Gastroenterol 2007;102:2181-8.
12. Pattullo V, Heathcote EJ, Wong DKH. Superior response to pegylated interferon and ribavirin in Asians with chronic hepatitis C. Hepatol Int 2010;4:723-31.
13. Yan KK, Guirgis M, Dinh T, et al. Treatment responses in Asians and Caucasians with chronic hepatitis C infection. World J Gastroenterol 2008;14:3416-20.
14. Hu K-Q, Freilich B, Brown RS, et al. Impact of Hispanic or Asian ethnicity on the treatment outcomes of chronic hepatitis C: results from the WIN-R Trial. J Clin Gastroenterol 2011;45:720-6.
15. Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009;461:399-401.
16. Suppiah V, Moldovan M, Ahlenstiel G, et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 2009;41:1100-4.
17. Tanaka Y, Nishida N, Sugiyama M, et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009;41:1105-9.
18. Thompson AJ, Muir AJ, Sulkowski MS, et al. Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology 2010;139:120.e18-9.e18.
19. Vutien P, Nguyen NH, Trinh HN, et al. Similar treatment response to peginterferon and ribavirin in Asian and Caucasian patients with chronic hepatitis C. Am J Gastroenterol 2010;105:1110-5.
20. Nguyen NH, Vutien P, Garcia RT, et al. Response to pegylated interferon and ribavirin in Asian American patients with Chronic hepatitis C genotypes 1 vs 2/3 vs 6. J Viral Hepat 2010;17:691-7.
21. Kin KC, Lin B, Ha NB, et al. High proportion of hepatitis C virus in community Asian American patients with non-liver-related complaints. J Clin Gastroenterol 2013;47:367-71.
22. Kin KC, Lin B, Chaung KT, et al. Less-established risk factors are common in Asian Americans with hepatitis C virus: a case-controlled study. Dig Dis Sci 2013;58:3342-7.
23. Nakamura M, Kanda T, Haga Y, et al. Sofosbuvir treatment and hepatitis C virus infection. World J Hepatol 2016;8:183-90.
24. Rembeck K, Lagging M. Impact of IL28B, ITPA and PNPLA3 genetic variants on therapeutic outcome and progression of hepatitis C virus infection. Pharmacogenomics 2015;16:1179-88.
25. Simeprevir [package insert]. Titusville, NJ: Janssen Therapeutics; February 2016.
26. Gane EJ, Stedman C, Hyland RH, et al. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N Engl J Med 2013;368:34-44.
27. Afdhal N, Reddy KR, Nelson DR, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 2014;370:1483-93.
28. Afdhal N, Zeuzem S, Kwo P, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 2014;370:1889-98.
29. Kowdley KV, Gordon SC, Reddy KR, et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med 2014;370:1879-88.
30. Jacobson IM, Gordon SC, Kowdley KV, et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med 2013;368:1867-77.
31. Lawitz E, Sulkowski MS, Ghalib R, et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. Lancet 2014;384:1756-65.
32. Lim Y-S, Ahn SH, Lee KS, et al. A phase IIIb study of ledipasvir/sofosbuvir fixed-dose combination tablet in treatment-naïve and treatment-experienced Korean patients chronically infected with genotype 1 hepatitis C virus. Hepatol Int 2016;23:358-65.
33. Chuang W-L, Chien R-N, Peng C-Y, et al. Ledipasvir/sofosbuvir fixeddose combination tablet in Taiwanese patients with chronic genotype 1 hepatitis C virus. J Gastroenterol Hepatol 2016;31:1323-9.
34. Mizokami M, Yokosuka O, Takehara T, et al. Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trial. Lancet Infect Dis 2015;15:645-53.
35. Nguyen MH, Whittemore AS, Garcia RT, et al. Role of ethnicity in risk for hepatocellular carcinoma in patients with chronic hepatitis C and cirrhosis. Clin Gastroenterol Hepatol 2004;2:820-4.
36. Fox DS, McGinnis JJ, Tonnu-Mihara I, et al. Comparative treatment effectiveness of direct acting antiviral regimens for hepatitis C: data from the Veterans Administration. J Gastroenterol Hepatol 2016; Epub ahead of print DOI: 10.1111/jgh.13652.
37. Roytman M, Ramkissoon R, Wu C, et al. Examining the clinical course of genotype 1 chronic hepatitis C patients treated with the cosmos regimen: including patients with advanced liver disease and East Asian ancestry. Hepatol Int 2016;10:616-23.
38. Omata M, Nishiguchi S, Ueno Y, et al. Sofosbuvir plus ribavirin in Japanese patients with chronic genotype 2 HCV infection: an open-label, phase 3 trial. J Viral Hepat 2014;21:762-8.
39. Ahn SH, Lim YS, Lee KS, et al. A phase 3b study of sofosbuvir plus ribavirin in treatment-naive and treatment-experienced Korean patients chronically infected with genotype 2 hepatitis C virus. J Viral Hepat 2016;23:358-65.
40. Morio K, Imamura M, Kawakami Y, et al. Real-world efficacy and safety of daclatasvir and asunaprevir therapy for hepatitis C virus-infected cirrhosis patients. J Gastroenterol Hepatol 2016; Epub ahead of print. DOI: 10.1111/jgh.13511.
41. Chan HL-Y, Tsang OT-Y, Hui Y-T, et al. Real-life efficacy and safety of paritaprevir/ritonavir, ombitasvir and dasabuvir in chronic hepatitis C patients in Hong Kong. J Gastroenterol Hepatol 2016; Epub ahead of print DOI: 10.1111/jgh.13663.
42. Kao JH, Chien RN, Chang TT, et al. A phase 3b study of sofosbuvir plus ribavirin in Taiwanese patients with chronic genotype 2 hepatitis C virus infection. Liver Int 2016;36:1101-7.
43. Zeuzem S, Dusheiko GM, Salupere R, et al. Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N Engl J Med 2014;370:1993-2001.
44. Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013;368:1878-87.
45. Foster GR, Afdhal N, Roberts SK, et al. Sofosbuvir and velpatasvir for HCV genotype 2&3 infection. N Engl J Med 2015;373:2599-607.
46. Gritsenko D, Hughes G. Ledipasvir/sofosbuvir (harvoni): improving options for hepatitis C virus infection. P T 2015;40:256-76.
47. Lai CL, Wong VW-S, Yuen MF, et al. Sofosbuvir plus ribavirin for the treatment of patients with chronic genotype 1 or 6 hepatitis C virus infection in Hong Kong. Aliment Pharmacol Ther 2016;43:96-101.